Medtech firm Stryker investing €200m in Irish R&D
Medical technology company Stryker is putting more than €200m into research and development (R&D) and innovation projects across three of its five Cork facilities.
Stryker employs more than 3,500 people in the Republic, mainly across its five sites in Cork, and at a facility in Limerick city which employs 770. The company also has an operation in Belfast with 170 staff.
Please log in or register with Independent.ie for free access to this article.
The investment is part of the company's drive to continue innovation in delivering products and services across its medical surgical, orthopaedics and neurotechnology and spine offerings.
The €200m progamme, which is supported by the Government through IDA Ireland, includes investments in projects at its AMagine Institute.
It develops products for three divisions, spine, craniomaxillofacial and joint replacement.
In addition, investment by the US-headquartered company will go into its neurovascular business, which develops stroke treatment products, and its Instruments Innovation Centre. The centre designs, develops and commercialises new surgical devices across a range of surgical procedures.
Spencer Stiles, group president, Instruments, Neurotechnology and Spine at Stryker, said: "At Stryker we are committed to making healthcare better for our customers and their patients.
"The continued growth and investment in Ireland is the result of many factors, inclusive of the research, development and innovation support from IDA Ireland and the partnerships built with leading Irish universities and research centres."
Last year, Stryker invested more than 6pc of its global sales into research and development.
The news was welcomed by both Minister for Business, Enterprise & Innovation, Heather Humphreys and IDA Ireland.